Ian Michael Estepan Sarepta Therapeutics, Inc. (SRPT) insider trading activity

Ian Michael Estepan is Chief Financial Officer of Sarepta Therapeutics, Inc.. Currently has a direct ownership of 46,883 shares of SRPT, which is worth approximately $5 Million. The most recent transaction as insider was on Jan 29, 2025, when has been sold 2,613 shares (Common Stock) at a price of $117.51 per share, resulting in proceeds of $307,053. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.9K

38.11% 3M change

19.86% 12M change

Total Value Held $5 Million

Ian Michael Estepan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 29 2025	SELL Payment of exercise price or tax liability	$307,053 $117.51 p/Share	2,613 Reduced 5.28%	46,883 Common Stock
Jan 29 2025	BUY Exercise of conversion of derivative security	$189,600 $12.0 p/Share	15,800 Added 24.2%	49,496 Common Stock
Dec 27 2024	SELL Bona fide gift	-	250 Reduced 0.74%	33,696 Common Stock
Aug 30 2024	SELL Open market or private sale	$822,099 $137.36 p/Share	5,985 Reduced 14.99%	33,946 Common Stock
Jun 24 2024	SELL Payment of exercise price or tax liability	$408,801 $164.64 p/Share	2,483 Reduced 5.85%	39,931 Common Stock
Jun 21 2024	BUY Exercise of conversion of derivative security	-	6,250 Added 12.84%	42,414 Common Stock
Mar 08 2024	SELL Payment of exercise price or tax liability	$127,449 $123.14 p/Share	1,035 Reduced 2.78%	36,164 Common Stock
Mar 07 2024	SELL Payment of exercise price or tax liability	$63,377 $120.49 p/Share	526 Reduced 1.39%	37,199 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$174,069 $125.32 p/Share	1,389 Reduced 3.55%	37,725 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$46,059 $126.19 p/Share	365 Reduced 1.05%	34,314 Common Stock
Mar 01 2024	SELL Open market or private sale	$153,960 $128.3 p/Share	1,200 Reduced 2.98%	39,114 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	6,000 Added 12.96%	40,314 Common Stock
Mar 08 2023	SELL Payment of exercise price or tax liability	$113,973 $153.19 p/Share	744 Reduced 2.1%	34,679 Common Stock
Mar 06 2023	SELL Payment of exercise price or tax liability	$215,377 $157.21 p/Share	1,370 Reduced 4.24%	30,923 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	4,500 Added 11.27%	35,423 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$55,781 $147.57 p/Share	378 Reduced 1.16%	32,293 Common Stock
Mar 07 2022	SELL Payment of exercise price or tax liability	$31,585 $79.36 p/Share	398 Reduced 1.59%	24,671 Common Stock
Mar 07 2022	BUY Grant, award, or other acquisition	-	8,000 Added 19.67%	32,671 Common Stock
Mar 04 2022	SELL Payment of exercise price or tax liability	$103,594 $79.2 p/Share	1,308 Reduced 4.96%	25,069 Common Stock
Mar 01 2022	SELL Payment of exercise price or tax liability	$28,219 $75.05 p/Share	376 Reduced 1.41%	26,377 Common Stock
Sep 08 2021	SELL Payment of exercise price or tax liability	$127,065 $78.29 p/Share	1,623 Reduced 5.72%	26,753 Common Stock
Mar 03 2021	BUY Grant, award, or other acquisition	-	15,000 Added 34.06%	29,042 Common Stock

IME

Ian Michael Estepan

Chief Financial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Value

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT

Account